1. Home
  2. EM vs CCCC Comparison

EM vs CCCC Comparison

Compare EM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Share Global Limited

EM

Smart Share Global Limited

HOLD

Current Price

$1.14

Market Cap

291.6M

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.12

Market Cap

240.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EM
CCCC
Founded
2017
2015
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
291.6M
240.3M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
EM
CCCC
Price
$1.14
$2.12
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$1.25
$7.25
AVG Volume (30 Days)
544.0K
1.7M
Earning Date
03-05-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$259,541,587.00
$30,108,000.00
Revenue This Year
$3.30
N/A
Revenue Next Year
$5.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$1.09
52 Week High
$1.46
$4.03

Technical Indicators

Market Signals
Indicator
EM
CCCC
Relative Strength Index (RSI) 32.67 46.02
Support Level $1.13 $2.02
Resistance Level $1.19 $2.47
Average True Range (ATR) 0.04 0.14
MACD 0.01 0.03
Stochastic Oscillator 72.71 41.67

Price Performance

Historical Comparison
EM
CCCC

About EM Smart Share Global Limited

Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: